TCW Concentrated Large Cap Growth Fund on Intuitive Surgical, Inc.
Thesis
Intuitive Surgical reported revenue and Da Vinci procedure growth above consensus while also raising 2026 guidance. TCW believes the company remains early in the Da Vinci 5 launch, which can expand penetration into additional hospitals and procedure categories. Its approximately 20-year lead over competitors and strong competitive moat support the fund's constructive long-term view despite recent pressure on high-multiple medtech stocks.
“we remain constructive on shares.”
Key risks
- System placements in China and Japan continue to disappoint.
- Negative investor sentiment toward health-care medtech stocks has pressured the shares.
- The stock remains a high-growth, high-multiple security.